Cart
sales@molnova.com
EMA300
CAS No. 136676-76-1
EMA300( PD121981 )
Catalog No. M11515 CAS No. 136676-76-1
EMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEMA300
-
NoteResearch use only, not for human use.
-
Brief DescriptionEMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R).
-
DescriptionEMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over AT1 receptor, produces analgesia in rodent model of neuropathic pain.
-
In Vitro——
-
In Vivo——
-
SynonymsPD121981
-
PathwayGPCR/G Protein
-
TargetAngiotensin Receptor
-
RecptorAngiotensin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number136676-76-1
-
Formula Weight495.579
-
Molecular FormulaC30H29N3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name1H-Imidazo[4,5-c]pyridine-6-carboxylic acid, 5-(diphenylacetyl)-4,5,6,7-tetrahydro-1-[(4-methoxy-3-methylphenyl)methyl]-, (S)- (9CI)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Smith MT, et al. Pain Med. 2013 Oct;14(10):1557-68.
2. Smith MT, et al. Behav Pharmacol. 2014 Apr;25(2):137-46.
3. Khan N, et al. Front Mol Neurosci. 2017 Nov 21;10:389.
4. Smith MT, et al. Pain Med. 2013 May;14(5):692-705.
molnova catalog
related products
-
PD 123319 ditrifluor...
A potent, selective, non-peptide AT2 receptor with IC50 of 34 nM.
-
EMA401
EMA401 (Olodanrigan) is a potent, highly selective angiotensin II type 2 receptor (AT2R) antagonist, inhibits capsaicin responses in cultured neurons of human and rat DRG with IC50 of 10 nM.
-
TD-0212
TD-0212 (TD0212) is a potent, orally efficacious, dual AT1 antagonist/Neprilysin (NEP) inhibitor with pKi of 8.9 (AT1) and pIC50 of 9.2 (NEP).
